Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study

NCT04515524 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04515524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04515524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
February 5, 2021
Completion date
November 5, 2026
Enrollment
100 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity